On 30 June 2026 South Korea’s Ministry of Food and Drug Safety published public notice 2026-311, a proposed amendment to the Food Code that would create a new food type, 세포배양가공식품 — cell-cultured processed food — with its own standards and specifications, and would require that any cell-cultured food ingredient used in food manufacture be one recognised under the ministry’s temporary standards regime. Comments were open until 31 August 2026.
That regime has been open since 22 February 2024. On that day MFDS promulgated the amendment to the Standards for Recognition of Temporary Standards and Specifications for Foods that added cell-cultured food ingredients to the list of things an applicant could ask it to recognise, set out the safety dossier required, and fixed a processing period of 270 days. Green Queen reported the same day that applications from local start-ups were expected “within the next few weeks”.
Thirty months separate the two notices. In that time no recognition of a cell-cultured ingredient has been published, MFDS has published no list of who applied, and the category that a recognised ingredient’s finished product would be sold under did not exist. The sequence is the story: Korea opened the door for the ingredient before it had decided what the product would be called, and any company that filed in 2024 has been waiting for a standard that was proposed in 2026.
The sequence, from the ministry’s notices
| Date | Instrument | What it did | Source |
|---|---|---|---|
| May 2023 | Amendment to the Enforcement Rule of the Food Sanitation Act | Extended the food-ingredient recognition regime to ingredients made by cell and microbial culture | 식품음료신문, citing MFDS |
| 26 October 2023 | Public notice 2023-507 | Proposed amendment to the temporary standards regime: add cell-cultured ingredients, define the dossier, “realistically” lengthen the processing period; comments to 26 December 2023 | MFDS |
| 22 February 2024 | Amended temporary standards promulgated | Cell-cultured food ingredients recognisable; dossier scope fixed; processing period 270 days; other categories lengthened from 30 to 120 days | 식품음료신문; Green Queen |
| August 2024 | MFDS dossier-preparation guide | Application checklist, data requirements, product-naming rules | Keller and Heckman, citing MFDS |
| 30 June 2026 | Public notices 2026-310 and 2026-311 | 311: new food type “cell-cultured processed food” (Food Code 제5. 21. 21-5) and a general requirement that cell-cultured ingredients be recognised ones; 310: replaces the term 세포배양물 with 세포배양식품원료 throughout; comments to 31 August 2026 | MFDS |
| 31 August 2026 | Comment period closes | Industry body asks for clarification of several definitions | 비건뉴스 |
The 2024 instrument is an ingredient route. It tells a company what to submit to have a cell-cultured material accepted as a food ingredient: the origin of the cells, the manufacturing process, species identity, cell-line characteristics, potential hazards, composition, intake and production controls, in 비건뉴스’s summary of the dossier. It does not say what the product made from a recognised ingredient is, for the purposes of the Food Code’s product-type standards, labelling and inspection.
The 2026 instrument is the product route. It creates the type, attaches standards and specifications to it, and — in the ministry’s own words in notice 2026-311 — establishes a general principle that cell-cultured ingredients may be used in food manufacture only if recognised under the 2024 regime. FoodNavigator quoted the minister, Oh Yoo-kyung, on the logic: at present such ingredients “may only be used in food products after they have been recognised by the criteria in the existing temporary standards”, and the ministry has “established new general standards for this” and will review current items “to move these up from the current temporary status”.
Read together, the two notices say that the 2024 route was always meant to be temporary — that is what 한시적 means — and that the permanent architecture arrived twenty-eight months later. An applicant who filed in March 2024 and received a decision on the 270-day clock would have held a recognised ingredient for more than a year with no product type to sell it under.
Practical consequence. For a company deciding where to file next, Korea’s route now has both halves. Until notice 2026-311 is finalised, though, a dossier filed under the 2024 standard is an application for an ingredient whose product category is still a draft, and the definitions industry has asked MFDS to clarify — see below — are the ones a launch depends on.
What the industry asked for on 31 August
비건뉴스 reports that the Bio-Future Food Industry Council of the Korea Bio Association submitted comments asking MFDS to make four things concrete: how the ingredient standard and the finished-product standard relate to each other; the definition of an edible scaffold — the material cells are grown on; what the 주원료 (main ingredient) requirement means; and the scope of application of the detailed specifications. The paper’s own gloss is the operative one: whether an early product containing a small proportion of cultured material falls inside the new type will affect both product development and the review.
Those are not drafting quibbles. The first Korean products will be ingredients inside conventional foods, on the companies’ own descriptions. Simple Planet, one of the companies preparing a Korean dossier, told Green Queen in June 2025 that it makes cell-cultured powders and pastes to be used as ingredients in snacks, beverages and ready meals, that it had completed proofs of concept with Nongshim and CJ, and that its production runs in 1,000-litre bioreactors with a capacity goal of 3.2 tonnes a month. Whether a granola bar with a few per cent of cultured powder is a “cell-cultured processed food”, with everything that implies for labelling and inspection, is exactly the question the council put.
There is a second consequence. Notice 2026-311 came with a regulatory impact analysis, the attachment used for proposals that create new regulatory burdens. The 비건뉴스 piece is explicit that finalising the notice does not in itself mean cultivated meat can be sold in Korea: company-by-company ingredient recognition and product conformity checks remain.
Practical consequence. A formulator planning a hybrid product for Korea should model two regulatory outcomes — inside the new type and outside it — because the threshold has not been set. The council’s comment is the best available guide to where the line will be argued.
Who applied, and what the 270 days became
MFDS does not publish a register of temporary-standard applications. That is not a Korean peculiarity — EFSA’s register shows validated dossiers, not decisions, and FDA’s GRAS inventory shows notices, not the self-affirmations that never reach it — but it means the only evidence of who filed is what companies and the press have said.
| Company | What is on the record | Source |
|---|---|---|
| CellMEAT | Green Queen in June 2025 cited a social-media report that MFDS was expected to clear a CellMEAT application “soon”; Health Korea News in January 2026 said CellMEAT and other domestic firms were going through the approval process and that a first domestic approval was expected within the year | Green Queen; 헬스코리아뉴스 |
| Simple Planet | Told Green Queen in June 2025 it was preparing dossiers for Korea and Singapore and aimed to file within the first half of 2025 | Green Queen |
| TissenBioFarm | Health Korea News reported it had completed technical validation with the aim of small-scale sales in 2026 | 헬스코리아뉴스 |
| Others named in trade coverage | Space F, SeaWith, Cellqua, and the KCell Biosciences facility with CJ CheilJedang in Busan | Green Queen, February 2024 |
None of these is a filing. We could not find an MFDS statement naming any applicant, and no company has published a receipt. If CellMEAT had filed by mid-2025, as the June 2025 report implies, then 270 days — nine months on the calendar, a little over a year if counted as working days — ran out in 2025 or early 2026, and the decision that was “expected soon” in June 2025 and within the year in January 2026 has still not been announced in September 2026.
Two readings fit the record. One is that the applications were delayed or withdrawn, and the 270-day clock never started. The other is that the ministry decided not to recognise an ingredient before it had a product type to put it in, and that the June 2026 notice is the unblocking step. The minister’s phrase about moving items “up from the current temporary status” supports the second reading; so does the fact that notice 2026-311 comes with a regulatory impact analysis, the document attached to proposals that create new obligations.
Practical consequence. The 270-day period is a processing target for a complete dossier, not a statutory deadline with consequences for the ministry, and the record shows it is not a forecast. Anyone building a Korean launch into a plan should date it from the finalisation of the product type, not from the filing.
Why Korea, and why it matters beyond Korea
FoodNavigator’s July piece carries a count from the Good Food Institute that explains the attention: by the end of 2025 South Korea had ten active specialised cultivated companies to Singapore’s eight, behind only the United States with 30, Israel with 16 and the United Kingdom with 14. The government has an enforced Food Tech Industry Promotion Act, a Food Tech Research Support Center for cultivated meat due to open in 2027 under the agriculture ministry, a regulation-free special zone in Gyeongbuk for tissue sampling and biopsies, and, per Health Korea News, a commercialisation support centre in Uiseong due for completion in 2027.
That is a lot of state investment in a sector whose regulatory route, until June, was half-built. It is also a pattern this publication has seen before. FSANZ’s second cell-cultured application skipped a consultation round because the first one had paid for the framework; Singapore’s own approved-foods list dates the first approval to 26 November 2020; in the EU, the opinion is not the approval and the gap ran to 320 days in 2026. In every jurisdiction the number that matters is not when the door opened but when the first product came through it, and Korea’s first product is still behind a draft.
The Korean case adds one thing to that list: a regulator that opened the ingredient route first and built the product route second, in public, with a two-year gap between them. For the companies that filed early, that was the wrong order. For the companies filing now, it may turn out to be the right one, because they will file into a complete framework and a 270-day clock that can, for the first time, run to a product.
The case that the sequence was correct
The ministry’s defenders would say the order was deliberate and sensible. Ingredient safety is the hard scientific question and the one that takes 270 days; a product type is a drafting exercise that can be done once the ministry has seen real dossiers and knows what products are coming. Writing the product standard in 2024, before any application, would have meant writing it blind. Doing it in 2026, with the industry’s own council commenting on scaffold definitions and inclusion thresholds, produces a better standard. On that view the thirty months are not a delay but the time it took to learn what to regulate, and the “temporary” label on the 2024 route was an honest description of a regime designed to be replaced.
That is a fair account of the ministry’s intent. It does not answer the question a company asks, which is what it was supposed to do with a recognised ingredient in 2025. And it does not explain why no recognition has been announced under a regime that has been open for thirty months and was described, by the regulator’s own count, as processing in 270 days.
What we could not establish
- Which companies have filed. No MFDS record names an applicant. The CellMEAT and Simple Planet entries above are press reports of intentions and expectations, not confirmed submissions.
- Whether any application has been decided. We found no recognition and no refusal in the public record. Absence of a published decision is not proof that none was made.
- The fee. Green Queen reported an application fee of ₩45 million in February 2024. We did not locate the fee in an MFDS instrument and have not repeated it in the body.
- Whether 270 days are working or calendar days. 식품음료신문 says “270일 이내”; Green Queen says “270 working days”. We have used the Korean report’s wording in the table and flagged the difference.
- The content of the draft product standard. Notice 2026-311 attaches the draft as an HWPX file; we have described it from the ministry’s summary and the trade reports, not from the attachment.
- The May 2023 date. 식품음료신문 attributes the extension of the ingredient regime to an amendment of the Enforcement Rule “last May” in a February 2024 article. We have not retrieved the Enforcement Rule amendment itself.
What to watch
- Finalisation of notice 2026-311 and whether the promulgated text answers the council’s four points, in particular the inclusion threshold for hybrid products.
- The first published recognition of a cell-cultured ingredient, and the date on it. Set beside the filing date, if the company discloses one, it will give the first measured processing time for the Korean route.
- Whether MFDS publishes an applicant list or a register as part of moving items “up from temporary status”. A public register would end the guesswork above.
- Simple Planet’s Singapore filing. The same company filing the same ingredient in two jurisdictions is the cleanest comparison the sector has been offered; the SFA decision will date the Korean one.
- The Uiseong and MAFRA centres in 2027. If they open before a product is on sale, Korea will have built the production support before the market, which is the order every other jurisdiction has managed to avoid only by not building the support.